Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
February 28, 2017 4:23 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
... More